University of Maryland, College Park
Trial Pipeline
Using the Smart Underwear Device to Determine a Baseline of Flatus Activity Normalized to Fiber Intake
NCT07134543
Effects of Youth Mental Health First Aid (YMHFA) on South Asian American Adults Working With South Asian American Youth
NCT07135479
Testing the Capability of the Smart Underwear Device to Detect Increased Microbiome Activity Following Lactose Consumption
NCT06724705
Neurocognitive Mechanisms of Sentence Production Impairment in Aphasia
NCT06405594
Longitudinal Investigation of Sleep, Memory, and Brain Development Across the Nap Transition
NCT06351098
Rosie the Chatbot: Leveraging Automated and Personalized Health Information Communication
NCT06053515
An Evaluation of an Online Sexual Assault Resistance Program (IDEA3)
NCT06058455
Peer Recovery to Improve Polysubstance Use and Mobile Telemedicine Retention
NCT05973838
Hands and Hearts Together
NCT05834907
Speech Perception and High Cognitive Demand
NCT04997577
Treating Parents with ADHD and Their Young Children Via Telehealth: a Hybrid Type I Effectiveness-Implementation Trial
NCT04240756
Helping College Students With ADHD Lead Healthier Lifestyles
NCT02829970
Writing About Experiences With Ovarian Cancer
NCT02593422
Implementation of Evidence-Based Cancer Early Detection in Black Churches
NCT02076958
Primary Prevention of Major Depression in Later Life
NCT00326677
Efficacy of Concerta in Treating ADHD in Mothers of Children With ADHD
NCT00318981
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
| Phase 4 | 1 |
What the Pipeline for University of Maryland, College Park Shows
According to the ClinicalTrials.gov registry, University of Maryland, College Park is linked to 43 US clinical trials across every stage of research activity. Of those, 37 studies are currently recruiting — about 86% of the sponsor's indexed portfolio — and 5 are already marked complete, representing roughly 12% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for University of Maryland, College Park reports 2 late-stage studies (Phase 3 and Phase 4 combined) and 0 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for University of Maryland, College Park is Substance-Related Disorders with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.